268 related articles for article (PubMed ID: 31894257)
1. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR‑125a‑5p.
Liu Y; Li M; Yu H; Piao H
Int J Mol Med; 2020 Feb; 45(2):497-509. PubMed ID: 31894257
[TBL] [Abstract][Full Text] [Related]
2. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
Han X; Li Q; Liu C; Wang C; Li Y
J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849
[TBL] [Abstract][Full Text] [Related]
3. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
4. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
5. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
[TBL] [Abstract][Full Text] [Related]
6. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
Li Z; Yu D; Li H; Lv Y; Li S
Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
Li X; Wu Y; Liu A; Tang X
Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
[TBL] [Abstract][Full Text] [Related]
8. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
[TBL] [Abstract][Full Text] [Related]
9. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
10. miR‑125a‑5p reverses epithelial‑mesenchymal transition and restores drug sensitivity by negatively regulating TAFAZZIN signaling in breast cancer.
Li D; Chen L; Zhang X; Wang Y; Huang C; Li J; He F; He W
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34549308
[TBL] [Abstract][Full Text] [Related]
11. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.
Wang J; Xie S; Yang J; Xiong H; Jia Y; Zhou Y; Chen Y; Ying X; Chen C; Ye C; Wang L; Zhou J
J Hematol Oncol; 2019 Jul; 12(1):81. PubMed ID: 31340867
[TBL] [Abstract][Full Text] [Related]
12. Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.
Zhang HY; Liang F; Zhang JW; Wang F; Wang L; Kang XG
Cancer Chemother Pharmacol; 2017 Feb; 79(2):327-337. PubMed ID: 28063065
[TBL] [Abstract][Full Text] [Related]
13. LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer.
Ma Y; Bu D; Long J; Chai W; Dong J
J Cell Physiol; 2019 Mar; 234(3):2880-2894. PubMed ID: 30203615
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance.
Sun W; Xu X; Jiang Y; Jin X; Zhou P; Liu Y; Guo Y; Ma D; Zuo W; Huang S; He X; Shao Z
Int J Cancer; 2019 Aug; 145(3):842-856. PubMed ID: 30720865
[TBL] [Abstract][Full Text] [Related]
15. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer.
Shi Q; Li Y; Li S; Jin L; Lai H; Wu Y; Cai Z; Zhu M; Li Q; Li Y; Wang J; Liu Y; Wu Z; Song E; Liu Q
Nat Commun; 2020 Nov; 11(1):5513. PubMed ID: 33139730
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA‑125a‑5p controls the proliferation, apoptosis, migration and PTEN/MEK1/2/ERK1/2 signaling pathway in MCF‑7 breast cancer cells.
Liang Z; Pan Q; Zhang Z; Huang C; Yan Z; Zhang Y; Li J
Mol Med Rep; 2019 Nov; 20(5):4507-4514. PubMed ID: 31702027
[TBL] [Abstract][Full Text] [Related]
17. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a].
Li XN; Liu AH; Tang X; Ren Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
19. CXCL10 mediates breast cancer tamoxifen resistance and promotes estrogen-dependent and independent proliferation.
Wu X; Sun A; Yu W; Hong C; Liu Z
Mol Cell Endocrinol; 2020 Jul; 512():110866. PubMed ID: 32417506
[TBL] [Abstract][Full Text] [Related]
20. Reduced Expression of
Yan X; Gao Z; Zhang L; Chen C
Anticancer Agents Med Chem; 2023; 23(8):929-937. PubMed ID: 36537604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
